BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
August 15, 2018 09:26 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
August 09, 2018 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of...
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
August 06, 2018 16:01 ET
|
Editas Medicine, Inc.
Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care EDIT-101 is Editas Medicine’s experimental CRISPR genome editing...
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
July 30, 2018 07:55 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with...
BioDelivery Sciences to Present at the William Blair 2018 Growth Stock Conference
June 01, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading specialty pharmaceutical company in the field of pain management and addiction...
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
May 23, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board
May 22, 2018 08:29 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering...
AGN: Rosen Law Firm Reminds Allergan, Inc. Investors of Important Deadline in Class Action – AGN
August 10, 2017 20:30 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan, Inc. (NYSE:AGN) from February 25, 2014 through April...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Allergan, Inc. – AGN
July 28, 2017 21:23 ET
|
The Rosen Law Firm PA
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Allergan,...
Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases
March 14, 2017 08:00 ET
|
Editas Medicine; Allergan plc
– Brings Together Eye Care and CRISPR Innovators to Develop Transformative Medicines for Patients – – Provides Allergan Exclusive Access to Multiple Editas Medicine Ocular Programs Based on its...